Fisher Strengthens its Reagent Portfolio Through Acquisition of BioImage
News Apr 28, 2006
BioImage, which is based in Copenhagen, Denmark, complements Fisher Biosciences' existing Cellomics business.
The Cellomics platform includes automated imaging instrumentation, BioApplication image analysis software, High Content Informatics software and HitKit® HCS Reagent kits.
The entire Cellomics product portfolio is fully integrated to improve the quality and productivity of high content cell-based assays.
BioImage is a leader in the field of High Content Pathway analysis, providing the life-science market with products, services and licenses that are based on its Redistribution® technology.
Redistribution is a patented technology that monitors protein translocation within a cell and is the basis for many of today's high content assays.
"The addition of BioImage further enhances our portfolio of high content cell-based assays and reagents," said Ron Lowy, president and chief executive officer of Fisher Biosciences.
"Adding BioImage's Redistribution IP, assays, cell-lines and services to our already strong offering of high content screening instrumentation, software, siRNA and assay reagent kits, provides a more complete range of options to customers and strengthens Fisher's leadership position in high content screening."
Fisher will continue operations in Copenhagen.
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018